GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Autobio Diagnostics Co 603658.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

39.21

-1.38%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Autobio Diagnostics Co

Its shares trade on Shanghai under the ticker 603658.SS. It has been listed since 1 September 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.23bn and net income of CN¥1.07bn. At that date it held total assets of CN¥12.29bn and shareholders' equity of CN¥8.93bn.

Autobio Diagnostics Co., Ltd. engages in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. The company is headquartered in Zhengzhou, Henan. The company went IPO on 2016-09-01. The firm's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The firm distributes its products in domestic markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
1 Sept 2016
Employees
5,505

Leadership

Pay as last reported

  • Mr. Yongjun MiaoChairman of the Board, since 2012CN¥1.1m
  • Mr. Yaxun ZhangVice Chairman of the Board, since 2006CN¥80,000
  • Ms. Chaojie FengChief Financial Officer, Deputy General Manager, Director, since 2012CN¥701,000
  • Mr. Zengli YangGeneral Manager, Director, since 2012CN¥734,200
  • Mr. Ruikuan FangDeputy General Manager, Secretary of the BoardCN¥673,200
  • Mr. Guangyu FuExecutive Deputy General Manager, DirectorCN¥698,400
  • Mr. Xuewei WuDeputy General Manager, Director, since 2012CN¥763,200
  • Mr. Ruifeng ZhangExecutive Deputy General Manager, Director, since 2018CN¥630,300
  • Ms. Yuanming QiIndependent DirectorCN¥13,300
  • Mr. Hailing QiaoIndependent Director
  • Ms. Xianghua ShenIndependent DirectorCN¥13,300
  • Mr. Huagang YuanIndependent DirectorCN¥13,300

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
38
Environment
42
Social
32
Governance
40
Women in the workforce
38.19505%
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Zhengzhou, Henan with 5,505 employees
  • Offers a range of in vitro diagnostic reagents and instruments
  • Provides immunodiagnostic and microbiology detection products

Weaknesses

  • Limited to domestic market distribution
  • No mention of international presence or expansion plans
  • Reliance on specific product categories without diversification

Opportunities

  • Potential for international market expansion
  • Growth in demand for diagnostic products in health care sector
  • Opportunities to diversify product offerings

Threats

  • Competition from other health care companies
  • Dependence on domestic market may limit growth
  • Rapid technological changes in diagnostic industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.